Zoetis

ZTS Healthcare & Pharma 4/10 Medium Risk
4/10
— 3 → 4 over 19 weeks
Sector avg: 3.1/10

Zoetis has $5.6B in scheduled debt maturities. Notably, the entire $5.6B maturity schedule falls within five years, creating a concentrated refinancing window. DebtCanary scores ZTS at 4/10, indicating moderate refinancing pressure.

Maturity Schedule

As of 2026-03-31 (latest SEC filing with maturity data). Debt actions taken after this date will only appear once SEC processes the relevant XBRL filing.
Year 1 $750M Year 2 $1.4B Year 3 $2.0B Year 4 $750M Year 5 $750M Beyond 5 $0
Period Amount Due % of Total
Year 1 (0-12 months) $750M 13.4%
Year 2 (12-24 months) $1.4B 24.1%
Year 3 (24-36 months) $2.0B 35.7%
Year 4 (36-48 months) $750M 13.4%
Year 5 (48-60 months) $750M 13.4%
Beyond 5 Years N/A N/A
Total Scheduled Maturities $5.6B 100.0%

Key Metrics

Total Long-Term Debt
N/A
Near-Term (12mo)
$750M
Interest Coverage
N/A
Debt/Equity
1.73
Cash Coverage
2.59x
Operating Income
N/A

Score Components

Component Value Weight
Near-Term Maturity Concentration 13.4% 30%
Interest Coverage Ratio N/A 25%
Debt-to-Equity Ratio 1.73 25%
Cash Coverage of Near-Term Debt 2.59x 20%

Recent SEC Filings

Material disclosures from Zoetis's most recent EDGAR filings. 8-K item labels indicate the type of event reported.

Date Form Details
2026-05-22 8-K Officer / Director Change, Shareholder Vote
2026-05-20 8-K Reg FD Disclosure
2026-05-07 10-Q Quarterly report
2026-05-07 8-K Earnings Results
2026-04-08 DEFA14A Additional proxy materials
2026-04-08 DEF 14A Proxy statement
2026-02-12 10-K Annual report
2026-02-12 8-K Earnings Results

Related Companies

Johnson & Johnson
JNJ
2/10
Debt: $41.4B 12mo: $2.0B
Pfizer
PFE
5/10
Debt: N/A 12mo: $3.9B
AbbVie
ABBV
4/10
Debt: $64.5B 12mo: $6.0B
Merck &
MRK
4/10
Debt: $49.1B 12mo: $2.6B
Eli Lilly
LLY
4/10
Debt: $29.5B 12mo: N/A
Bristol Myers Squibb
BMY
5/10
Debt: $44.1B 12mo: $2.0B
Amgen
AMGN
5/10
Debt: $57.3B 12mo: $4.6B
Gilead Sciences
GILD
2/10
Debt: $22.2B 12mo: $1.3B

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Fiscal period end: 2026-03-31. Filing date: 2026-05-07. Data last fetched: 2026-07-05. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Partial.
View SEC EDGAR filings for Zoetis →